Document is current
Any future updates will be listed below
-
Authors
Hengeveld, Paul J. https://orcid.org/0000-0002-0070-138X
Schilperoord-Vermeulen, Joyce
Kolijn, P. Martijn
Dubois, Julie M. N.
Westerweel, Peter E. https://orcid.org/0000-0002-0746-7039
Kersting, Sabina
Kater, Arnon P. https://orcid.org/0000-0003-3190-1891
Levin, Mark-David https://orcid.org/0000-0003-2139-3547
Langerak, Anton W. https://orcid.org/0000-0002-2078-3220
- License Information
-
More Information
Article History
Received: 27 June 2024
Revised: 12 December 2024
Accepted: 2 January 2025
First Online: 7 January 2025
Competing interests
: JMND has received research funding from Roche/Genentech. SK has received personal fees from Janssen, AbbVie, Novartis, Gilead, and Celgene; and research funding from AbbVie, Janssen, AstraZeneca, and Roche/Genentech. APK has received personal fees from AbbVie, LAVA, Genmab, Janssen, AstraZeneca, Roche/Genentech, and Bristol Myers Squibb; and research funding from AbbVie, Janssen, AstraZeneca, Roche/Genentech, and Bristol Myers Squibb. AWL has received research funding via an unrestricted grant from Roche-Genentech and speaker-fees from Janssen. M-DL has received personal fees from AbbVie, Janssen, and Roche; and research funding from AbbVie, Janssen, AstraZeneca, and Roche/Genentech. The remaining authors declare no competing financial interests.
